Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914607 | 0.78 | PTGS1 (0.37) | PTGS1PTGS2NFE2L2GRIN2DGRIN3B | |
| SCHEMBL8441698 | 0.73 | NFE2L2 (0.35) | PTGS1PTGS2NFE2L2GRIN2DGRIN3B | |
| SCHEMBL7923573 | 0.73 | NFE2L2 (0.42) | PTGS1PTGS2NFE2L2GRIN2DGRIN3B | |
| SCHEMBL7926808 | 0.71 | POLB (0.40) | PTGS1PTGS2 | |
| SCHEMBL7923592 | 0.70 | PTGS1 (0.37) | PTGS1PTGS2NFE2L2GRIN2DGRIN3B | |
| SCHEMBL7914568 | 0.69 | NFE2L2 (0.32) | PTGS1PTGS2NFE2L2 | |
| SCHEMBL7926748 | 0.67 | AR (0.36) | NFE2L2 | |
| SCHEMBL7920979 | 0.64 | ALDH1A1 (0.33) | — | |
| SCHEMBL18862550 | 0.63 | SLC6A2 (0.36) | — | |
| SCHEMBL17040782 | 0.63 | SLC6A2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194461-B1 | USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0945426-A1 | NITRONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-09-29 | — | — | EP | disclosed |